Department of Surgery, Aga Khan University, Karachi, Pakistan.
Division of Thoracic Surgery, Department of Surgery, JFK University Medical Center, Hackensack Meridian Health, Edison, NJ, USA.
Ann Surg Oncol. 2023 Oct;30(10):5965-5973. doi: 10.1245/s10434-023-13887-5. Epub 2023 Jul 18.
There is no consensus on the use of postoperative antibiotic prophylaxis (PAP) after mastectomy with indwelling drains. We explored the utility of continued PAP in reducing surgical site infection (SSI) rates after mastectomy without immediate reconstruction and with indwelling drains.
A multicenter, two-armed, randomized control superiority trial was conducted in Pakistan. We enrolled all consenting adult patients undergoing mastectomy without immediate reconstruction. All patients received a single preoperative dose of cephalexin within 60 min of incision, and postoperatively were randomized to receive either continued PAP using cephalexin (intervention) or a placebo (control) for the duration of indwelling, closed-suction drains. The primary outcome was the development of SSI within 30 days and 90 days postoperatively. Secondary outcomes included study-drug-associated adverse events. Intention-to-treat analysis was performed using multivariable Cox regression.
A total of 369 patients, 180 (48.8%) in the intervention group and 189 (51.2%) in the control group, were included in the final analysis. Overall cumulative SSI rates were 3.5% at 30 days and 4.6% at 90 days postoperatively. PAP was not associated with SSI reduction at 30 (hazard ratio, HR 1.666 [95% confidence interval CI 0.515-5.385]) or 90 (1.575 [0.558-4.448]) days postoperatively, or with study-drug-associated adverse effects (0.529 [0.196-1.428]).
Continuing antibiotic prophylaxis for the duration of indwelling drains after mastectomy without immediate reconstruction offers no additional benefit in terms of SSI reduction. There is a need to update existing guidelines to provide clearer recommendations regarding use of postoperative antibiotic prophylaxis after mastectomy in the setting of indwelling drains.
目前对于留置引流管的乳房切除术术后是否使用预防性抗生素(PAP)尚无共识。我们探讨了在不立即重建且留置引流管的情况下继续使用 PAP 以降低乳房切除术后手术部位感染(SSI)率的效果。
本研究在巴基斯坦进行了一项多中心、双臂、随机对照优效性试验。我们招募了所有同意接受乳房切除术但不立即重建的成年患者。所有患者在切开后 60 分钟内接受单次术前头孢氨苄治疗,术后随机接受头孢氨苄(干预组)或安慰剂(对照组)持续 PAP,持续时间为留置闭式引流管的时间。主要结局是术后 30 天和 90 天内发生 SSI。次要结局包括与研究药物相关的不良事件。采用多变量 Cox 回归进行意向治疗分析。
共有 369 例患者,干预组 180 例(48.8%),对照组 189 例(51.2%),最终纳入分析。总体累积 SSI 率分别为术后 30 天 3.5%和 90 天 4.6%。PAP 与术后 30 天(风险比,HR 1.666 [95%置信区间 CI 0.515-5.385])或 90 天(1.575 [0.558-4.448])时 SSI 减少无关,也与研究药物相关的不良事件无关(0.529 [0.196-1.428])。
对于不立即重建的乳房切除术后留置引流管期间继续使用抗生素预防治疗并不能降低 SSI 的发生率。有必要更新现有的指南,以提供更明确的关于留置引流管情况下乳房切除术后术后使用抗生素预防的建议。